We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Neogen (NEOG) Launches Dairy Toxin Detection Test Reveal Q+
Read MoreHide Full Article
Neogen Corporation (NEOG - Free Report) recently launched Reveal Q+ — a faster and easier test to detect aflatoxin M1. For investors note, afltoxin M1 is a carcinogenic metabolite of aflatoxin B1. It is a known cancer-causing toxin produced in the rumen of dairy cattle, a concern for the global dairy industry.
Notably, the new test integrated with Neogen's Raptor Integrated Analysis Platform controls the timing, temperature and reading of the test strip and enables testers to simply add sample and walk away.
With the recent launch, Neogen aims to strengthen its Food Safety business on a global scale.
Significance of the Launch
Neogen’s new Revel Q+ is intended to detect as little as 150 ppt of the Aflatoxin M1 in milk samples within few minutes. The new test can detect aflatoxin M1 in milk within a range of 150-600 ppt. In many countries, including the United States and Brazil, the available tests have a regulatory limit of 500 ppt for aflatoxin M1. This will facilitate dairy processors to simplify screening of Aflatoxin M1 in raw milk and dairy products.
Reveal Q+ is integrated with Raptor system and simplifies the testing process. With this launch, dairy processors can simultaneously test one sample for the presence of aflatoxin M1 and classes of dairy antibiotics like beta-lactams and tetracyclines. Additionally, the raptor system safeguards the integrity and consistency of testing data by processing and analyzing results without additional operator input.
Notable Developments in Food Safety
In January 2021, Neogen acquired Ireland-based Megazyme, Ltd. — a major supplier of analytical solutions used by quality control laboratories in the global food and beverage industries. The integration of Megazyme product line into Neogen’s food safety products will expand commercial relationship with food companies across the globe as well as provide foods with highest quality and nutritional value.
In December 2020, Neogen launched the quickest and easiest tests to determine meat speciation in raw meat and environmental sample. The new Reveal tests for horse, beef, sheep, and poultry provide accurate results in five minutes after a simple water extraction. It helps prevent the accidental or deliberate inclusion of other meats in raw processed meats and to validate cleaning following product changeovers.
Industry Prospects
Per a report by Grand View Research, the global food safety testing market size was estimated at $18.0 billion in 2018 and is anticipated to witness a CAGR of 7.7% by 2025. Growing demand for packaged and processed food globally owing to changing lifestyle and growing popularity of quick-service restaurants is driving the need for safety testing of edible items. Moreover, the rising demand for quality tests for processed and unprocessed meats is expected to fuel the food safety testing market growth.
Price Performance
Shares of the company have rallied 21.9% in a year’s time compared with the industry’s growth of 4.8%.
Zacks Rank and Key Picks
Currently, Neogen carries a Zacks Rank # 5 (Strong Sell)
Some better-ranked stocks from the broader medical space include Quidel Corporation (QDEL - Free Report) , AdaptHealth Corp. (AHCO - Free Report) and Owens& Minor, Inc. (OMI - Free Report) . While both Quidel and AdaptHealth sports a Zacks Rank # 1 (Strong Buy), Owens & Minor carries a Zacks Rank # 2 (Buy). You can see the complete list of Zacks #1 Rank stocks here.
Quidel has a projected long-term earnings growth rate of 25%
AdaptHealth has a projected long-term earnings growth rate of 753.3%
Owens & Minor has an estimated long-term earnings growth rate of 48.9%
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Neogen (NEOG) Launches Dairy Toxin Detection Test Reveal Q+
Neogen Corporation (NEOG - Free Report) recently launched Reveal Q+ — a faster and easier test to detect aflatoxin M1. For investors note, afltoxin M1 is a carcinogenic metabolite of aflatoxin B1. It is a known cancer-causing toxin produced in the rumen of dairy cattle, a concern for the global dairy industry.
Notably, the new test integrated with Neogen's Raptor Integrated Analysis Platform controls the timing, temperature and reading of the test strip and enables testers to simply add sample and walk away.
With the recent launch, Neogen aims to strengthen its Food Safety business on a global scale.
Significance of the Launch
Neogen’s new Revel Q+ is intended to detect as little as 150 ppt of the Aflatoxin M1 in milk samples within few minutes. The new test can detect aflatoxin M1 in milk within a range of 150-600 ppt. In many countries, including the United States and Brazil, the available tests have a regulatory limit of 500 ppt for aflatoxin M1. This will facilitate dairy processors to simplify screening of Aflatoxin M1 in raw milk and dairy products.
Reveal Q+ is integrated with Raptor system and simplifies the testing process. With this launch, dairy processors can simultaneously test one sample for the presence of aflatoxin M1 and classes of dairy antibiotics like beta-lactams and tetracyclines. Additionally, the raptor system safeguards the integrity and consistency of testing data by processing and analyzing results without additional operator input.
Notable Developments in Food Safety
In January 2021, Neogen acquired Ireland-based Megazyme, Ltd. — a major supplier of analytical solutions used by quality control laboratories in the global food and beverage industries. The integration of Megazyme product line into Neogen’s food safety products will expand commercial relationship with food companies across the globe as well as provide foods with highest quality and nutritional value.
In December 2020, Neogen launched the quickest and easiest tests to determine meat speciation in raw meat and environmental sample. The new Reveal tests for horse, beef, sheep, and poultry provide accurate results in five minutes after a simple water extraction. It helps prevent the accidental or deliberate inclusion of other meats in raw processed meats and to validate cleaning following product changeovers.
Industry Prospects
Per a report by Grand View Research, the global food safety testing market size was estimated at $18.0 billion in 2018 and is anticipated to witness a CAGR of 7.7% by 2025. Growing demand for packaged and processed food globally owing to changing lifestyle and growing popularity of quick-service restaurants is driving the need for safety testing of edible items. Moreover, the rising demand for quality tests for processed and unprocessed meats is expected to fuel the food safety testing market growth.
Price Performance
Shares of the company have rallied 21.9% in a year’s time compared with the industry’s growth of 4.8%.
Zacks Rank and Key Picks
Currently, Neogen carries a Zacks Rank # 5 (Strong Sell)
Some better-ranked stocks from the broader medical space include Quidel Corporation (QDEL - Free Report) , AdaptHealth Corp. (AHCO - Free Report) and Owens& Minor, Inc. (OMI - Free Report) . While both Quidel and AdaptHealth sports a Zacks Rank # 1 (Strong Buy), Owens & Minor carries a Zacks Rank # 2 (Buy). You can see the complete list of Zacks #1 Rank stocks here.
Quidel has a projected long-term earnings growth rate of 25%
AdaptHealth has a projected long-term earnings growth rate of 753.3%
Owens & Minor has an estimated long-term earnings growth rate of 48.9%
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>